0 évaluation0% ont trouvé ce document utile (0 vote)
55 vues3 pages
Ranbaxy is an international pharmaceutical company serving customers in over 150 countries for more than 50 years. It is a member of the Daiichi Sankyo Group, a leading global pharma innovator headquartered in Tokyo, Japan. Ranbaxy has ground operations in 30 countries and 21 manufacturing facilities across 10 countries, covering all major pharmaceutical markets worldwide.
The DuPont analysis breaks down return on equity (ROE) into profit margin, asset turnover, and equity multiplier. Applying it to Ranbaxy, its net profit margin was the highest contributor to ROE in 2011, while asset turnover was highest in 2010. So profitability played a larger role in 2011's returns, while operational efficiency mattered more for
Ranbaxy is an international pharmaceutical company serving customers in over 150 countries for more than 50 years. It is a member of the Daiichi Sankyo Group, a leading global pharma innovator headquartered in Tokyo, Japan. Ranbaxy has ground operations in 30 countries and 21 manufacturing facilities across 10 countries, covering all major pharmaceutical markets worldwide.
The DuPont analysis breaks down return on equity (ROE) into profit margin, asset turnover, and equity multiplier. Applying it to Ranbaxy, its net profit margin was the highest contributor to ROE in 2011, while asset turnover was highest in 2010. So profitability played a larger role in 2011's returns, while operational efficiency mattered more for
Ranbaxy is an international pharmaceutical company serving customers in over 150 countries for more than 50 years. It is a member of the Daiichi Sankyo Group, a leading global pharma innovator headquartered in Tokyo, Japan. Ranbaxy has ground operations in 30 countries and 21 manufacturing facilities across 10 countries, covering all major pharmaceutical markets worldwide.
The DuPont analysis breaks down return on equity (ROE) into profit margin, asset turnover, and equity multiplier. Applying it to Ranbaxy, its net profit margin was the highest contributor to ROE in 2011, while asset turnover was highest in 2010. So profitability played a larger role in 2011's returns, while operational efficiency mattered more for
Ranbaxy Laboratories Limited (Ranbaxy) is a research based international
pharmaceutical company serving customers in over 150 countries. For more than 50 years, e have been providing high !uality, a""ordable medicines trusted by healthcare pro"essionals and patients across geographies. Ranbaxy is a member o" the #aiichi $an%yo &roup. #aiichi $an%yo is a leading global pharma innovator, head!uartered in 'o%yo, (apan. )e have ground operations in *+ countries and ,1 manu"acturing "acilities spread across - countries. )e cover all the top ,5 pharmaceutical mar%ets o" the orld and have a robust presence across both developed and emerging mar%ets. DUPONT ANALYSIS :- #u.ont analysis (also %non as the dupont identity, #u.ont e!uation, #u.ont /odel or the #u.ont method) is an expression hich brea%s R01 (Return 0n 1!uity2) into three parts. 'he name comes "rom the #u.ont 3orporation2 that started using this "ormula in the 14,0s. 'he #u .ont identity brea%s don Return on 1!uity (that is, the returns that investors receive "rom the "irm) into three distinct elements. 'his analysis enables the analyst to understand the source o" superior (or in"erior) return by comparison ith companies in similar industries (or beteen industries). 'he #u .ont identity is less use"ul "or industries such as investment ban%ing, in hich the underlying elements are not meaning"ul. 5ariations o" the #u .ont identity have been developed "or industries here the elements are ea%ly meaning"ul. #u .ont analysis relies upon the accounting identity2, that is, a statement ("ormula) that is by de"inition. R01 6 (.ro"it margin)7(8sset turnover)7(1!uity multiplier) 6 (9et pro"it2:$ales2)7($ales2:8ssets2)7(8ssets2:1!uity2)6 (9et .ro"it:1!uity) .ro"itability (measured by pro"it margin2) 0perating e""iciency (measured by asset turnover2) Financial leverage2 (measured by e!uity multiplier2) DUPONT ANALYSIS OF RANBAXY LIMITED 9et income o" ranbaxy is ,01,;,1<4.*, crore,,011;(,+4<1.-- ).sales is ,01,; <11,*.*+crore,,011; -0+<+.-,, assets ,01,; <+1+5.*+ crore , ,011; ,,,<.,1,and e!uity ,01,; ,11*.5= crore ,,011; ,110.00 crore. High turnovr in!u"tri" 3ertain types o" retail operations, particularly stores, may have very lo pro"it margins on sales, and relatively moderate leverage. >n contrast, though, groceries may have very high turnover, selling a signi"icant multiple o" their assets per year. 'he R01 o" such "irms may be particularly dependent on per"ormance o" this metric, and hence asset turnover may be studied extremely care"ully "or signs o" under;, or, over;per"ormance. 9et income :sales is ,01,; ,1<4.*,:<11,*.*+ is 0.0+5 ,011;,+,4<1.--:-0+<+.-, is ,.-4 High #$rgin in!u"tri" 0ther industries, such as "ashion, may derive a substantial portion o" their competitive advantage "rom selling at a higher margin, rather than higher sales. For high;end "ashion brands, increasing sales ithout sacri"icing margin may be critical. 'he #u .ont identity allos analysts to determine hich o" the elements is dominant in any change o" R01. $ales:assets is ,01,; <11,*.*,:<+1+5.*+ is 0.4<- ,011;<11,*.*+:,,,<.,1 is ,=.*< High %vr$g in!u"tri" $ome sectors, such as the "inancial sector, rely on high leverage to generate acceptable R01. 0ther industries ould see high levels o" leverage as unacceptably ris%y. #u .ont analysis enables third parties that rely primarily on the "inancial statements to compare leverage among similar companies. 8ssets:e!uity is ,01,; <+1+5.*+:,11*.5= is ,4.-5 ,011;,,,<.,1:,110.00 is 1.055 $o leverage ratio is highest hich contribute more to return on e!uity "or year ,01, and 9et margin ratio is highest "or year ,011.
Payment or Compensation Received For Services or Employment. This Includes The Base Salary and Any Bonuses or Other Economic Benefits That An Employee or Executive Receives During Employment